Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report), retaining the price target of $45.00.
Sam Slutsky’s rating is based on the promising potential of Abivax’s obefazimod in the treatment of ulcerative colitis (UC). The company recently hosted a key opinion leader event featuring Professor David T. Rubin, who highlighted the growing prevalence and market size of inflammatory bowel diseases, including UC, which affects a significant portion of the population. The anticipated Phase 3 data for obefazimod, expected in the third quarter of 2025, adds to the optimism surrounding the drug’s potential impact.
Moreover, the current treatment landscape for UC includes various mechanisms such as anti-TNF, anti-IL-23, JAK inhibitors, and others, yet there remains a substantial opportunity for new therapies that offer better disease control. The positive topline Phase 2b data from JNJ/Protagonist’s oral IL-23r inhibitor further underscores the potential for oral therapies in this space. Slutsky’s Buy rating reflects confidence in Abivax’s ability to capitalize on these opportunities and deliver a novel treatment option for UC patients.
Slutsky covers the Healthcare sector, focusing on stocks such as Immunovant, Astria Therapeutics, and Oruka Therapeutics. According to TipRanks, Slutsky has an average return of -6.5% and a 31.25% success rate on recommended stocks.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $33.00 price target.